TheraRadar
Data updated: Mar 29, 2026

TRIFERIC AVNU

FERRIC PYROPHOSPHATE CITRATE
Approved 2020-03-27
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
6
Years on Market

Details

Status
Discontinued
First Approved
2020-03-27
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

ROCKWELL MEDICAL INC
Active Ingredient: FERRIC PYROPHOSPHATE CITRATE

TRIFERIC AVNU Approval History

Loading approval history...

What TRIFERIC AVNU Treats

1 FDA approvals

Originally approved for its first indication in 2020 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TRIFERIC AVNU FDA Label Details

Pro

TRIFERIC AVNU Patents & Exclusivity

Latest Patent: Apr 2029

Patents (1 active)

US7816404 Expires Apr 17, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA212860 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.